TERT and neoplasm: Among the mechanisms leading to aberrant telomerase activation, TERT promoter mutations C228T and C250T (−124 bp and −146 bp upstream of TERT’s transcription starting site, respectively) are frequent in cancer and associated with increased aggressiveness and metastatic potential in several tumor settings.